Pfizer and Moderna pledge to deliver COVID-19 booster shots by September

Trending News 🌥️

Pfizer ($NYSE:PFE) and Moderna have pledged to deliver booster shots of their COVID-19 vaccines by September, in response to the Biden administration’s plans to launch a campaign against the BA.5 subvariant of the virus. This should protect against the dominant form of the virus currently circulating in the United States. It is not yet clear how this will affect Pfizer’s market and earnings in the long term, but it is likely that the company will see increased demand for its vaccines in the near future.

Market Reaction

This news has caused PFIZER stock to open at $50.6 and close at $50.5 on Friday.

VI Analysis

Pfizer is a large pharmaceutical company with a long history. Its fundamentals reflect its long-term potential, and the company has a strong balance sheet.

However, its share price has been under pressure in recent years due to various headwinds, including increased competition, patent expirations, and regulatory scrutiny. Based on the VI Risk Rating, Pfizer is a medium risk investment in terms of financial and business risk. The company’s business risk is driven by factors such as competition, regulation, and patent expiration. Its financial risk is driven by its high debt levels and its reliance on sales of its blockbuster drugs. Investors should be aware of these risks before investing in Pfizer.

Summary

Despite this, experts believe that the long-term outlook for both companies is still positive, and that their stock prices will rebound in the coming months. For investors, this presents an opportunity to buy shares in both companies at a discounted price.